Legal Representation
Attorney
Bryce J. Maynard
USPTO Deadlines
Next Deadline
522 days remaining
Section 71 Declaration Due (Principal Register 66a) (Based on registration date 20210706)
Due Date
July 06, 2027
Grace Period Ends
January 06, 2028
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
36 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Dec 4, 2021 | NREP | P | NEW REPRESENTATIVE AT IB RECEIVED | Loading... |
| Nov 23, 2021 | FINO | P | FINAL DECISION TRANSACTION PROCESSED BY IB | Loading... |
| Nov 1, 2021 | FICS | P | FINAL DISPOSITION NOTICE SENT TO IB | Loading... |
| Nov 1, 2021 | FIMP | P | FINAL DISPOSITION PROCESSED | Loading... |
| Oct 6, 2021 | FICR | P | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | Loading... |
| Jul 6, 2021 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| May 4, 2021 | LIME | I | LIMITATION FROM THE IB EXAMINED AND ENTERED | Loading... |
| May 1, 2021 | LIMG | M | LIMITATION OF GOODS RECEIVED FROM IB | Loading... |
| Apr 20, 2021 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Apr 20, 2021 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Apr 18, 2021 | GPNX | P | NOTIFICATION PROCESSED BY IB | Loading... |
| Mar 31, 2021 | OPNS | P | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | Loading... |
| Mar 31, 2021 | OP2R | P | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | Loading... |
| Mar 31, 2021 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Mar 13, 2021 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Mar 13, 2021 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
| Mar 13, 2021 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
| Mar 13, 2021 | GNEA | O | EXAMINERS AMENDMENT E-MAILED | Loading... |
| Mar 13, 2021 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
| Mar 6, 2021 | GNS3 | O | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | Loading... |
| Mar 6, 2021 | GNSL | S | LETTER OF SUSPENSION E-MAILED | Loading... |
| Mar 6, 2021 | CNSL | R | SUSPENSION LETTER WRITTEN | Loading... |
| Jan 28, 2021 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Jan 28, 2021 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Jan 27, 2021 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Oct 16, 2020 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Jul 30, 2020 | NREP | P | NEW REPRESENTATIVE AT IB RECEIVED | Loading... |
| May 29, 2020 | RFNT | P | REFUSAL PROCESSED BY IB | Loading... |
| May 14, 2020 | RFCS | P | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | Loading... |
| May 14, 2020 | RFRR | P | REFUSAL PROCESSED BY MPU | Loading... |
| Apr 30, 2020 | RFCR | E | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | Loading... |
| Apr 29, 2020 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Apr 20, 2020 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Apr 17, 2020 | MAFR | O | APPLICATION FILING RECEIPT MAILED | Loading... |
| Apr 13, 2020 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Apr 9, 2020 | REPR | M | SN ASSIGNED FOR SECT 66A APPL FROM IB | Loading... |
Detailed Classifications
Class 005
Pharmaceutical preparations and substances for the treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies in the nature of mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism, lysosomal storage disorders and urea cycle disorders; pharmaceutical preparations, namely, a drug delivery system comprising genetically engineered and purified exosomes in the form of a liquid solution and lyophilised preparation for therapeutic use in the nature of treatment of for the treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies in the nature of mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism, lysosomal storage disorders and urea cycle disorders; pharmaceutical preparations, namely, exosomes to deliver protein for genetic therapy; Medicine for treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies in the nature of mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism, lysosomal storage disorders and urea cycle disorders; biological preparations for the treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies such as mitochondrial disease, joint and ligament strains and tears, muscle atrophy, muscular dystrophy; mixed biological preparations for the prevention and treatment of infectious diseases; EV-based nucleic acid therapeutics in the nature of pharmaceuticals, medicines, biologics, biotherapeutics, biosimilars, and therapeutics for the prevention and treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies in the nature of mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism, lysosomal storage disorders and urea cycle disorders; diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection; diagnostic kits comprised of medical diagnostic reagents and assays that test for the presence of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies in the nature of mitochondrial disease, joint strains and tears, ligament strains and tears, muscle atrophy, and muscular dystrophy
First Use Anywhere:
0
First Use in Commerce:
0
Class 044
Medical services; medical and pharmaceutical consultancy; medical services relating to the diagnosis and treatment of persons; medical analysis service relating to the diagnosis and treatment of persons provided by medical laboratories; medical analysis and examinations for the diagnosis of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies in the nature of mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, rare diseases, genetic diseases, in-born errors of metabolism, lysosomal storage disorders and urea cycle disorders; medical treatment services in the field of biotherapeutics for the treatment of infectious diseases, cancer, neurological disorders, neurodegenerative disorders, inflammatory disorders, rare diseases, genetic and metabolic disorders; medical screening; medical monitoring, testing, inspection and analysis services relating to the diagnosis and treatment of viral and bacterial based infections and diseases; medical monitoring, testing, inspection and analysis services relating to the diagnosis and treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies in the nature of mitochondrial disease, joint and ligament strains and tears, muscle atrophy, muscular dystrophy
First Use Anywhere:
0
First Use in Commerce:
0
Additional Information
Pseudo Mark
DELIVER EX
Classification
International Classes
005
044